HSDT · Helius Medical Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.62M | - | $697.0K | $43.0K | $49.0K | - | $51.0K | $182.0K | $135.0K | - |
| Cost of Revenue | $121.0K | - | $103.0K | $96.0K | $121.0K | - | $187.0K | $118.0K | $123.0K | - |
| Gross Profit | $3.44M | - | $594.0K | ($53.0K) | ($72.0K) | - | ($136.0K) | $64.0K | $12.0K | - |
| R&D | - | - | $858.0K | $822.0K | $945.0K | - | $1.08M | $870.0K | $788.0K | - |
| SG&A | $5.19M | - | $4.65M | $2.45M | $2.99M | - | $2.85M | $2.46M | $2.63M | - |
| Total Operating Expenses | $103.06M | - | $36.04M | $3.27M | $3.94M | - | $3.93M | $3.33M | $3.43M | - |
| D&A | - | - | - | - | $8.0K | - | - | - | $9.0K | - |
| Operating Income | ($99.62M) | - | ($35.45M) | ($3.32M) | ($4.01M) | - | ($4.07M) | ($3.27M) | ($3.42M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | ($99.80M) | - | ($352.77M) | ($9.83M) | ($3.84M) | - | ($3.69M) | ($1.61M) | ($2.52M) | - |
| EPS - Basic | ($1.30) | - | ($32.89) | ($79.73) | ($382.50) | - | ($742.50) | ($480.00) | ($2310.00) | - |
| EPS - Diluted | ($1.30) | - | ($32.89) | ($79.73) | ($382.50) | - | ($742.50) | ($480.00) | ($2310.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.39M | $7.28M | $124.05M | $6.08M | $1.11M | $1.09M | $3.47M | $6.39M | $3.64M | $5.18M |
| Accounts Receivable | - | - | - | $12.0K | - | $70.0K | $25.0K | $121.0K | $49.0K | $117.0K |
| Inventory | - | $1.12M | $1.13M | $1.14M | $1.11M | $1.04M | $774.0K | $821.0K | $384.0K | $457.0K |
| Accounts Payable | $2.00M | $1.89M | $2.48M | $1.29M | $1.23M | $873.0K | $743.0K | $1.29M | $814.0K | $531.0K |
| Current Assets | $27.84M | $31.16M | $125.66M | $7.80M | $3.38M | $3.42M | $5.41M | $8.64M | $5.52M | $7.44M |
| Total Assets | $200.71M | $303.93M | $475.92M | $7.89M | $3.48M | $3.54M | $5.58M | $8.85M | $5.76M | $7.69M |
| Current Liabilities | $2.81M | $3.02M | $3.14M | $1.80M | $2.00M | $2.16M | $1.50M | $2.06M | $1.58M | $1.88M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | $3.02M | $628.31M | $1.87M | $2.20M | $2.48M | $1.79M | $2.51M | $3.77M | $5.34M |
| Stockholders' Equity | $197.90M | $300.91M | ($152.39M) | $6.03M | $1.28M | $1.06M | $3.80M | $6.34M | $1.99M | $2.35M |
| Retained Earnings | ($312.39M) | ($212.59M) | ($538.14M) | ($185.37M) | ($175.54M) | ($171.70M) | ($167.77M) | ($164.09M) | ($162.47M) | ($159.96M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.83M) | - | - | - | ($3.54M) | - | - | - | ($3.00M) | - |
| Investing Cash Flow | $5.47M | - | - | - | - | - | - | - | ($5.0K) | - |
| Financing Cash Flow | ($3.52M) | - | - | - | $3.56M | - | - | - | $1.46M | - |
| CapEx | - | - | - | - | - | - | - | - | $5.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($3.01M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 95.0% | - | 85.2% | -123.3% | -146.9% | - | -266.7% | 35.2% | 8.9% | - |
| Operating margin | -2751.1% | - | -5086.1% | -7725.6% | -8185.7% | - | -7980.4% | -1796.7% | -2530.4% | - |
| EBITDA margin | - | - | - | - | -8169.4% | - | - | - | -2523.7% | - |
| Net margin | -2756.1% | - | -50612.3% | -22867.4% | -7832.7% | - | -7227.5% | -885.7% | -1863.7% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -2226.7% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.19 | - |
| R&D / Revenue | - | - | 123.1% | 1911.6% | 1928.6% | - | 2111.8% | 478.0% | 583.7% | - |
| SG&A / Revenue | 143.3% | - | 666.6% | 5690.7% | 6110.2% | - | 5588.2% | 1350.0% | 1950.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -49.7% | - | -74.1% | -124.6% | -110.2% | - | -66.0% | -18.2% | -43.7% | - |
| Return on equity | -50.4% | - | 231.5% | -163.2% | -299.8% | - | -97.0% | -25.4% | -126.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.90 | 10.33 | 40.03 | 4.32 | 1.69 | 1.58 | 3.61 | 4.20 | 3.51 | 3.96 |
| Quick ratio | 9.90 | 9.96 | 39.67 | 3.69 | 1.13 | 1.10 | 3.10 | 3.80 | 3.26 | 3.72 |
| Cash ratio | 1.56 | 2.41 | 39.52 | 3.37 | 0.55 | 0.50 | 2.32 | 3.11 | 2.31 | 2.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.01 | 1.01 | -3.12 | 1.31 | 2.72 | 3.34 | 1.47 | 1.40 | 2.90 | 3.27 |
| Liabilities / Assets | - | 0.01 | 1.32 | 0.24 | 0.63 | 0.70 | 0.32 | 0.28 | 0.66 | 0.69 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.00 | 0.01 | 0.01 | - | 0.01 | 0.02 | 0.02 | - |
| Inventory turnover | - | - | 0.09 | 0.08 | 0.11 | - | 0.24 | 0.14 | 0.32 | - |
| Days sales outstanding | - | - | - | 102d | - | - | 179d | 243d | 132d | - |
| Days inventory outstanding | - | - | 3997d | 4338d | 3357d | - | 1511d | 2540d | 1140d | - |
| Days payable outstanding | 6042d | - | 8806d | 4912d | 3713d | - | 1450d | 3981d | 2416d | - |
| Cash conversion cycle | - | - | - | -472d | - | - | 239d | -1199d | -1144d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.7x | - | - | 0.2x | 1775.4x | - | 414.3x | 292.0x | 1799.5x | - |
| P / S | 36.7x | - | 229.1x | 26.1x | 46378.5x | - | 30860.2x | 10169.1x | 26472.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 7289.8% | - | 1266.7% | -76.4% | -63.7% | - | -64.3% | -28.9% | 21.6% | - |
| Revenue CAGR (3y) | 219.5% | - | 52.6% | -28.8% | -36.3% | - | -22.4% | 36.9% | 17.1% | - |
| Revenue CAGR (5y) | 112.3% | - | 39.7% | -20.2% | -25.0% | - | -19.4% | -18.9% | -27.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | -209.1% | -11.1% | - | - |
| Operating income growth (YoY) | -2383.6% | - | -771.0% | -1.6% | -17.4% | - | -29.1% | -1.6% | 10.3% | - |
| Net income growth (YoY) | -2500.3% | - | -9470.5% | -510.0% | -52.5% | - | -0.6% | 2.2% | -0.9% | - |
| EPS growth (YoY) | 99.7% | - | 95.6% | 83.4% | 83.4% | - | -13424.6% | -799900.0% | -2566566.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 6.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 15360.7% | 28314.8% | - | -4.9% | -35.5% | -54.9% | 25.8% | 38.6% | -67.3% | -71.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$357.0K totalProduct$229.0K · 64.1%
Product And Service Other$128.0K · 35.9%
Peer comparison
Same SIC group: Finance Services
Comparing HELIUS MEDICAL TECHNOLOGIES against the 5 most active filers in the same SIC group.